Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by deepoil0808on Oct 30, 2021 12:40pm
152 Views
Post# 34068326

RE:RE:RE:Target Price: $ 1.48 per share (within 12 months)

RE:RE:RE:Target Price: $ 1.48 per share (within 12 months)Lets do the math per the information that is available to us:

July 2021 - Actutal figures                       $ 4,000,000  +/-  (1,000 patients per day)

Aug 1 to Aug 15 estimated                         2,000,000  (keeping it same as July 2021 rate, 1,000 patients/day)

August 15 to August 31                              6,000,000  (based on lawyer saying patients tripled to 3,000/day)

Sept 01 to Sept 30:                                  12,000,000  (based on lawyer saying patients tripled to 3,000/day)

Total Projected Revenue:                         24,000,000


Following complaints with the two (2) cubes in California, the MEDV lawyer replied to the authorities giving as an explanation that patients served at MEDV cubes was 3,000 patients per day (triple amount from July) and that cubes were not built for this amount of people.

We have also indirect confirmation from many parties that there were 3 1/2 hour long waits to get tested.

This gives credence to the tripling of patients. 

California has a law in place that those whom are unvaccinated need to be tested weekly.   This can explain the surge in patients.

I actually believe that the numbers will be much higher because I have not accounted for vaccination rates, nor for testing done at schools or at employers. 

Like I said, I am projecting the future.   It is always difficult to do as the past is easy to analyze but the future is more challenging. 

In any event, we are moving towards TELEHEALTH market which is an $ 800 billion gorilla and, this market will provide much needed stability and recurring revenue to MEDV.

Give David Preiner a chance, he gives me the impression of someone whom wants to succeed and is a no nonsense person, not afraid to make decisions that are not beneficial to MEDV shareholders (ie:  like cancelling Blowme transaction, like cancelling Marbella acquisition, like cleaning up the balance sheet, like convincing debt holders to become long term stock holders, etc...)

The previous CED Doug Sommerville did significant damage to the credibility of MEDV, he had a big mouth and nothing to show for it.    David Preiner is quiet, he has a vision and numbers will speak for themselves.

Those who believe in him better LOAD UP cause once numbers are in you will be chasing the stock.

My price target:    $ 1.48 per share (within 12 months)


<< Previous
Bullboard Posts
Next >>